VIVUS Inc

VIVUS — Technical Presentation (June 2010)

20 slides from VIVUS's technical presentation, Jun 21, 2010

  1. Slide 1: Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight

    W. Timothy Garvey, MD Chair, Department of Nutrition Sciences Professor of Nutrition Sciences University of Alabama at Birmingham Staff Physician and GRECC Investigator Birmingham Veterans Affairs Medical Center Birmingham, Alabama Charles H. Bowden, MD Barbara Troupin, MD Wesley W. Day, PhD Vivus,

  2. Slide 2: Disclosures

    Disclosures Dr. Garvey has the following financial relationships to disclose: Research support – Merck & Co., Inc.; Isis/Genzyme; Amylin Pharmaceuticals Speakers Bureau – Merck & Co., Inc; Abbott Nutrition Advisor/consultant – Daiichi-Sankyo; Tethys; Vivus, Inc. Board member – Daiichi-Sankyo, Tethys

  3. Slide 3: Obesity: An Escalating Public Health Issue

    Obesity: An Escalating Public Health Issue Obesity is associated with significantly increased morbidity, mortality related to cardiovascular disease, diabetes1,2 Potential health benefits from reduction in obesity are of considerable public health importance3 10% initial weight loss is recommended g

  4. Slide 4: Phentermine and Topiramate

    Phentermine and Topiramate Phentermine (PHEN)1 FDA-approved (1959) as a short-term adjunct to diet and exercise Acts primarily through appetite suppression Topiramate (TPM) Neurotherapeutic agent approved for seizure disorders (1996) and migraine headache prophylaxis (2004)2 Demonstrated weight loss

  5. Slide 5: PHEN/TPM CR is an investigational, fixed-dose combination weight-loss therapy

    PHEN/TPM CR is an investigational, fixed-dose combination weight-loss therapy PHEN and TPM have demonstrated weight loss through different mechanisms1 Greater response seen with combination than with either agent alone, allowing for lower doses of each agent1 Complementary mechanisms may reduce/coun

  6. Slide 6: CONQUER: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

    CONQUER: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial PHEN/TPM CR 7.5/46 mg or 15/92 mg vs placebo 56 weeks of treatment in overweight/obese adults with >2 weight-related comorbidities BMI >27 kg/m2 to <45 kg/m2* Comorbidities include: Dyslipidemia (elevated trig

  7. Slide 7: Outcomes of Interest

    Outcomes of Interest Primary endpoints: Mean percent weight loss at Week 56 Percentage of subjects losing >5% of body weight at Week 56 Secondary/other endpoints included: Percentage of subjects losing >10% of body weight at Week 56 Changes in cardiometabolic markers Lipids Glycemic parameters Infla

  8. Slide 8: CONQUER Study Design

    CONQUER Study Design Dosing and Randomization Placebo (n=994) PHEN/TPM CR 7.5/46 (n=498) PHEN/TPM CR 15/92 (n=995) Total (N=2487)

  9. Slide 9: Baseline Demographics

    Baseline Demographics Placebo (n=994) PHEN/TPM CR 7.5/46 (n=498) 15/92 (n=995) Age (years), mean (SD) 51.2 (10.3) 51.1 (10.4) 51.0 (10.7) Female, n (%) 695 (69.9) 349 (70.1) 693 (69.6) Race Caucasian 86.6% 86.1% 85.4% African 11.5% 11.2% 12.3% Weight (kg), mean (SD) 103.3 (18.1) 102.6 (18.2) 103.0 (

  10. Slide 10: Mean Percent Weight Loss

    Mean Percent Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo

  11. Slide 11: Subjects With >5% Weight Loss

    Subjects With >5% Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo ITT-LOCF Study Completers 20.8% 26.2% 62.1%* 74.6%* 70.0%* 85.1%* 0 10 20 30 40 50 60 70 80 90 ITT-LOCF Study Completers % of Subjects

  12. Slide 12: Subjects With >10% Weight Loss

    Subjects With >10% Weight Loss at Week 56: ITT-LOCF, Study Completers *P<0.0001 vs placebo ITT-LOCF Study Completers

  13. Slide 13: Change (%) in Lipid Parameters

    Change (%) in Lipid Parameters at Week 56: ITT-LOCF *P<0.05 vs placebo TC LDL-C HDL-C TG Baseline Mean (mg/dL): 206 201 205 124 120 124 49 49 49 164 161 162

  14. Slide 14: Changes in Glycemic Parameters

    Changes in Glycemic Parameters at Week 56: ITT-LOCF Baseline Mean 106.6 106.2 105.7 5.9 5.9 5.9 n: 938 473 954 805 449 895 Fasting Glucose (mg/dL) HbA1c (%) *P<0.005 vs placebo

  15. Slide 15: Changes in Insulinemic Parameters

    Changes in Insulinemic Parameters at Week 56: ITT-LOCF Fasting Insulin (uIU/mL) HOMA-IR *P<0.001 vs placebo 15 Baseline Mean 17.8 18.0 18.4 5.2 4.9 5.3 n: 925 464 937 925 464 937

  16. Slide 16: Changes in hsCRP, Adiponectin

    Changes in hsCRP, Adiponectin at Week 56: ITT-LOCF Baseline mean: 6.4 7.0 6.5 8.0 8.1 7.9 n: 777 440 880 737 419 836 *P<0.0001 vs placebo hsCRP=high-sensitivity C-reactive protein hsCRP (mg/L) Adiponectin (ug/mL)

  17. Slide 17: Changes in Fibrinogen

    Changes in Fibrinogen at Week 56: ITT-LOCF Baseline mean: 459.6 459.6 454.4 n: 737 416 842 *P<0.05 vs placebo Fibrinogen (mg/dL)

  18. Slide 18: Treatment-Emergent Adverse Events Reported in >5% of CONQUER Subjects

    Treatment-Emergent Adverse Events (AEs) Reported in >5% of CONQUER Subjects: Safety Set Adverse Event (Preferred Term) Placebo (n=993) (%) 7.5/46 (n=498) (%) 15/92 (n=994) (%) Dry mouth 2.4 13.5 20.8 Paresthesia 2.0 13.7 20.5 Constipation 5.9 15.1 17.4 Upper respiratory tract infection 12.9 12.2 13.

  19. Slide 19: Safety Summary

    Safety Summary Most AEs were mild/moderate in severity Similar incidences of AEs by severity across treatment groups Treatment-emergent serious AEs comparable: 3.8% in placebo vs 3.8% in all PHEN/TPM CR Discontinuation rates due to treatment-emergent AEs: 8.9% for placebo 11.6% for 7.5/46 19.2% for

  20. Slide 20: Conclusions

    Conclusions PHEN/TPM CR led to significant weight loss vs placebo at 56 weeks PHEN/TPM CR improved all measured cardiometabolic risk factors – lipid, glycemic, inflammatory, coagulation factors Greater weight loss seen with the 15/92 dose was associated with greater improvements in important risk ma

Vivus — Technical Presentation (June 2010) on 6ix